ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Halberd Corp (PK)

Halberd Corp (PK) (HALB)

0.0037
-0.0001
(-2.63%)
Closed January 20 4:00PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.0037
Bid
0.0032
Ask
0.0037
Volume
131,250
0.003 Day's Range 0.0038
0.00235 52 Week Range 0.0121
Market Cap
Previous Close
0.0038
Open
0.003
Last Trade
100
@
0.0037
Last Trade Time
Financial Volume
$ 443
VWAP
0.003373
Average Volume (3m)
675,319
Shares Outstanding
635,880,000
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-0
Revenue
1,000
Net Profit
-80k

About Halberd Corp (PK)

Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurologic and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the speci... Halberd Corp is a research-based company seeking to develop treatments for a range of diseases. Their extracorporeal method treats blood-borne, neurologic and infectious diseases. Halberd's patents remove bodily fluids in a continuous fashion, like dialysis, or in a batch process. To treat the specific disease, the treatment is applied to the bodily fluid. Disease eradication via exposure to radio frequency, laser irradiation, or chemical bonding. The cleansed bodily fluids are then returned to the patient without deadly side effects found with injected or ingested medications. Halberds technology base is 4 issued patents and 22 pending patents: Current projects with planned submissions of abstracts to ARPA-H include: * Extracorporeal eradication of inflammatory cytokines from cerebrospinal fluid associated with PTSD and Suicidal Ideation * Therapeutic lozenges to alleviate pain and anxiety as well as chemical and alcohol addiction * Eradication of antibiotic-resistant bacteria and deadly Candida Auris fungi supplied by CDC * Development of a nasal spray is in pre-clinical testing designed to eliminate neurodegenerative cascade associated of head trauma * Extracorporeal eradication of antigens associated with cancer * Extracorporeal eradication of the 10 inflammatory cytokines & the excitatory neurotransmitter associated with Alzheimer's Disease, Parkinson's Disease & Epilepsy * Development of antibodies against Coronavirus & extracorporeal eradication of Covid antigens. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Headquarters
Huntington Woods, Michigan, USA
Founded
-
Halberd Corp (PK) is listed in the Medical Laboratories sector of the OTCMarkets with ticker HALB. The last closing price for Halberd (PK) was $0. Over the last year, Halberd (PK) shares have traded in a share price range of $ 0.00235 to $ 0.0121.

Halberd (PK) currently has 635,880,000 shares outstanding. The market capitalization of Halberd (PK) is $2.42 million. Halberd (PK) has a price to earnings ratio (PE ratio) of 0.00.

HALB Latest News

WNRS - Winners Inc Maintains VERY BULLISH Posture - $0.05 Alternative To $50 Draft Kings (DKNG)

July 28, 2021 -- InvestorsHub NewsWire -- via pennymillions Winners, Inc. (WNRS) is growing. It’s signing one sports book after another as the legal online sports betting industry...

WSGF - With Vaycaychella's Q2 Launch Imminent, World Series of Golf Inc.'s Stock Is In Play

April 21, 2021 -- via MarketScreener.com   With World Series of Golf, Inc.'s (OTC Pink: WSGF) Vaycaychella nearing its planned Q2 launch, WSGF stock looks...

Immune Therapeutics, Inc.(Ticker: IMUN) Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs

October 21, 2020 -- InvestorsHub NewsWire -- via Stock Investor Wire -- Cytocom, Inc. , a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., an...

Fintech SPAC Boom Could Ignite Existing Fintechs Like IQST

  October 19, 2020 -- InvestorsHub NewsWire -- via pennymillions/IQST -- This past summer saw multiple special purpose acquisition company (SPAC) IPOs targeting the...

PAOG CEO On MoneyTV This Friday Discussing Latest CBD Bio Pharma Developments

Sandusky, OH -- September 14, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today announced an interview of CEO James C. DiPrima on MoneyTV with Donald Baillargeon...

Halberd Corporation's Subsidiary Aspyre.com Enters Into Strategic Partnership With Positive Impact Magazine

Halberd Corporation's Subsidiary Aspyre.com Enters Into Strategic Partnership With Positive Impact Magazine PR Newswire SOUTHFIELD, Mich., July 29, 2014 SOUTHFIELD, Mich., July 29, 2014...

Halberd Corporation's New Subsidiary Aspyre.com Discusses Revenue Streams

Halberd Corporation's New Subsidiary Aspyre.com Discusses Revenue Streams PR Newswire SOUTHFIELD, Mich., July 22, 2014 SOUTHFIELD, Mich., July 22, 2014 /PRNewswire/ -- Halberd Corporation (OTC...

Halberd Corporation Acquires Crowd Connex Corporation And Its Subsidiary Aspyre.com

SOUTHFIELD, Mich., July 9, 2014 /PRNewswire/ - Halberd Corporation (OTC Market: HALB) acquires Tampa Bay based Crowd Connex Corporation. Crowd Connex Corporation owns Aspyre.com a secure online...

Halberd Corporation Responds To False Press Release Issued By SMSW Corporation

Halberd Corporation Responds To False Press Release Issued By SMSW Corporation PR Newswire SOUTHFIELD, Mich., July 8, 2014 SOUTHFIELD, Mich., July 8, 2014 /PRNewswire/ -- Halberd Corporation (OTC...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0004-9.756097560980.00410.00450.0034744800.00390267CS
40.000619.35483870970.00310.00450.0036280420.00406026CS
12-0.0005-11.90476190480.00420.00460.002356753190.00373404CS
26-0.0038-50.66666666670.00750.00890.002358126180.0050483CS
52-0.00245-39.8373983740.006150.01210.002359730020.00712332CS
156-0.0167-81.8627450980.02040.02810.0023511883480.01094316CS
2600.0025208.3333333330.00120.1090.000444644930.02893521CS

HALB - Frequently Asked Questions (FAQ)

What is the current Halberd (PK) share price?
The current share price of Halberd (PK) is $ 0.0037
How many Halberd (PK) shares are in issue?
Halberd (PK) has 635,880,000 shares in issue
What is the market cap of Halberd (PK)?
The market capitalisation of Halberd (PK) is USD 2.42M
What is the 1 year trading range for Halberd (PK) share price?
Halberd (PK) has traded in the range of $ 0.00235 to $ 0.0121 during the past year
What is the reporting currency for Halberd (PK)?
Halberd (PK) reports financial results in USD
What is the latest annual turnover for Halberd (PK)?
The latest annual turnover of Halberd (PK) is USD 1,000
What is the latest annual profit for Halberd (PK)?
The latest annual profit of Halberd (PK) is USD -80k
What is the registered address of Halberd (PK)?
The registered address for Halberd (PK) is 10755 VERNON AVENUE, HUNTINGTON WOODS, MICHIGAN, 48070
Which industry sector does Halberd (PK) operate in?
Halberd (PK) operates in the MEDICAL LABORATORIES sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TMGIMarquie Group Inc (PK)
$ 0.0002
(19,900.00%)
4.03M
SEANSAEAN Group Inc (PK)
$ 1.87
(18,600.00%)
100
ZPASZoompass Holdings Inc (CE)
$ 0.0001
(9,900.00%)
675
GMPRGourmet Provisions International Corporation (PK)
$ 0.0001
(9,900.00%)
35.31M
PLPLPlandai Biotechnology Inc (PK)
$ 0.0001
(9,900.00%)
18.06M
STNXStartronix International Inc (CE)
$ 0.000001
(-99.99%)
450
AWINAERWINS Technologies Inc (CE)
$ 0.000001
(-99.97%)
2.03k
ISOLImage Software Inc (CE)
$ 0.000001
(-99.91%)
59.2k
NBIONascent Biotech Inc (CE)
$ 0.0002
(-99.55%)
8.7k
FHBCFernhill Beverage Inc (CE)
$ 0.000001
(-99.24%)
10k
GTCHGBT Technologies Inc (PK)
$ 0.0001
(0.00%)
349.77M
VTXBVortex Brands Company (PK)
$ 0.0002
(0.00%)
297.52M
EMEDElectroMedical Technologies Inc (PK)
$ 0.0002
(0.00%)
233.53M
PHILPHI Group Inc (PK)
$ 0.0002
(-33.33%)
184.12M
HMBLHUMBL Inc (PK)
$ 0.0009
(-5.26%)
179.2M

HALB Discussion

View Posts
work-n-hard work-n-hard 4 weeks ago
Getting ready for another PR?
👍️0
Jimmyarich Jimmyarich 1 month ago
.0032 dumbass
👍️0
work-n-hard work-n-hard 1 month ago
The typical "dumper", OTCN hasn't even been in play. So it's this low because nobody wants it.
Perhaps paying .32 was too much. Might have to buy some lower, in order to squeeze out another win. SMH
👍️0
squidster squidster 1 month ago
$1100 in volume LMAO

Back at you
👍️0
work-n-hard work-n-hard 1 month ago
No it wasn't. But it's hard to tell that after the post prior to mine ended up missing. (As you can see, mine was temporarily missing also.
You can believe that you would have gotten a chuckle, had the "context" not gone away.

Hope all is well with you & yours.
👍️0
squidster squidster 1 month ago
Pretty sure this was meant for someone else.
I know you flip the POS better than most...
HALB ready for liftoff, just waiting on news.LMFAO
👍️0
squidster squidster 1 month ago
Total number of shareholders of record: 88

Convertible Judgments Payable and Contingent Liabilities:
As of July 31, 2024, there was a balance outstanding of $ 104,525 on this judgment that could be converted into approximately
298,642,911 shares of the Company’s common stock at a rate of approximately $0.00035 per share

Common Stock Warrants:
Warrants to purchase a total of 584,000,000 shares of common stock at a weighted average strike price of $0.01 were outstanding as of
July 31, 2024.

882,642,911 shares pending issuance and we all understand there are 800,000,000 authorized shares and 635,874,842 issued...

What does that mean for the 88 bagholders of HALB...

"answers" are "solutions" SMFH
👍️0
work-n-hard work-n-hard 2 months ago
Cheap enough, just don't make us sit on them too long.
But will take some 20's.
👍️0
retired early retired early 2 months ago
Exactly. :)
👍️0
Aero-man Aero-man 2 months ago
These bashing-losers on this board have all the "answers" but have ZERO solutions. Don't listen to their blathering-lunacy, that's all.
🤢 1 🤥 1
work-n-hard work-n-hard 2 months ago
You should listen to others and "smarten up". lol You know what is much smarter than flipping from lows to highs?
It's putting your money in a ticker that shows that it can't hold any high ground for long and letting your money sit dead for months or even years.
Not to mention, that when & if you ever get to cash in, the opportunity cost have eaten away at your profits.
Uh? Wait a minute.....that doesn't sound right? Hmmmm? 🤔
(Folks are often oblivious to Opportunity Costs.)
👍️0
Aero-man Aero-man 2 months ago
You bashers need to smarten up and realize that this small bio-tech company is struggling to get new products into the market, which takes much time and effort. Added to that is the fact that this company has to deal with bureaucratic red tape from such big-government-agencies as the FDA and DOD, which even takes more time and effort. In addition, to get through FDA studies and bureaucratic-hoops takes several years.

This means that all systems are go to move forward with expanded studies, which looks good for new funding from gov'mnt and private sources.
👍️ 2
retired early retired early 2 months ago
Testing testing testing. It's how it works to become legit. :)
👍️0
squidster squidster 2 months ago
What exaclty does this mean for HALB?
👍️0
work-n-hard work-n-hard 2 months ago
Paragraph 2 Translation: Getting ready for more dilution.
JMO
👍️0
Aero-man Aero-man 2 months ago
More great news just released from Halberd:

JACKSON CENTER, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January.

We are awaiting government and pending private investment funding to accelerate the 100-person study currently underway.

https://finance.yahoo.com/news/halberd-watchdawg-ptsd-treatment-130000055.html
👍️0
work-n-hard work-n-hard 2 months ago
HALB:
👍️0
squidster squidster 2 months ago
Shocking 😆
👍️0
Kool Aid Man Kool Aid Man 2 months ago
I have--Heard anything more about that $2 million grant from ESC? It's been going into Spooz (SPZI). Randall's involved behind the curtain. A new front man installed Dec 8th. A/S completely maxed out yet new management claims they own ZERO shares (except the Super Vote). Their "YUGGE NEWS" always followed by a drop in share price. ESC= tax evasion and money laundering IMO
👍️0
docsetc docsetc 2 months ago
The ultimate scam continues.
👍️0
Huggy Bear Huggy Bear 3 months ago
Uh huh, suuuure.
👍️0
work-n-hard work-n-hard 3 months ago
This is one sucky Annual. Revenue Down, shares Up and soon, so will the AS's. (Be up)
And don't even get me started on those Judgements + Warrants.
Without a R/S, the PPS is going to find a home in the trips. Nobody is buying their shares now, wait until they are forced to step up the selling.
🤪

https://www.otcmarkets.com/stock/HALB/disclosure
👍️0
squidster squidster 3 months ago
$900 in daily volume
HALB=POS
👍️0
pistol2 pistol2 3 months ago
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Press Release | 10/01/2024
JACKSON CENTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wore a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participant data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health.

During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.

Dr. Mark Darrah, CEO of Athena GTX, stated, “The results of this Pilot Study are very encouraging. We met all of our objectives set for this effort, helped the participants with improved health, and discovered ways we can improve the treatment methodology going forward. The proprietary LDX/CBN combination and specialized yoga/meditation positively impacted health and wellness, and the data acquisition system effectively supported participants. We will use what we learned plus feedback from participants to improve the treatment protocol as we proceed to a 100-patient Phase 1 clinical trial.”

Dr. Darrah continued, “As we enter the next programmed step, we wanted to remind any interested parties to consider enrolling in or supporting Phase 1 trials. This is an open invitation to witness first-hand the value and ease of the therapy and its impact.”

William A. Hartman, President and CEO of Halberd Corporation, added, “The results thus far indicate the treatment methodology is having very promising results in the long-term care and treatment of patients suffering from PTSD and associated physical health issues. We remain hopeful that this will result in a widely accepted standard of care.”

Note: The full Athena GTX WatchDawg press release can be accessed via this link.

To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).

For more information please contact:

William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC
0Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Press Release | 10/01/2024
JACKSON CENTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wore a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participant data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health.

During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.

Dr. Mark Darrah, CEO of Athena GTX, stated, “The results of this Pilot Study are very encouraging. We met all of our objectives set for this effort, helped the participants with improved health, and discovered ways we can improve the treatment methodology going forward. The proprietary LDX/CBN combination and specialized yoga/meditation positively impacted health and wellness, and the data acquisition system effectively supported participants. We will use what we learned plus feedback from participants to improve the treatment protocol as we proceed to a 100-patient Phase 1 clinical trial.”

Dr. Darrah continued, “As we enter the next programmed step, we wanted to remind any interested parties to consider enrolling in or supporting Phase 1 trials. This is an open invitation to witness first-hand the value and ease of the therapy and its impact.”

William A. Hartman, President and CEO of Halberd Corporation, added, “The results thus far indicate the treatment methodology is having very promising results in the long-term care and treatment of patients suffering from PTSD and associated physical health issues. We remain hopeful that this will result in a widely accepted standard of care.”

Note: The full Athena GTX WatchDawg press release can be accessed via this link.

To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).

For more information please contact:

William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC


👍️ 1 🤣 1
Aero-man Aero-man 3 months ago
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

JACKSON CENTER, Pa., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with the Halberd/Athena teams and to fund key advanced research, including the pending FDA IND study utilizing Halberd’s LDX technology and Athena Corporation’s WatchDawg™ monitoring technology.

Defense Atomics Corporation agreed to use its proprietary CRISPR/Nanotechnology Stem Cell treatment for PTSD/TBI in a minimum of 10 paid veterans in a government pilot study of this cutting-edge protocol. Based on Defense Atomics’ success using CRISPR methodology with overseas patients, this study is intended to substantiate the benefits of this technology in conjunction with Halberd/Athena’s LDX PTSD and TBI/Brain Injury protocol.

https://finance.yahoo.com/news/halberd-partnership-secures-contract-defense-120000500.html
👍️ 1
docsetc docsetc 3 months ago
Ohhh, a tenderfoot.
👍️0
retired early retired early 3 months ago
Resorting to name calling. Wow tough guy. :) Here's your previous quote> "Sure. Have not owned a share of this for over 6 years now." So get the f out then. :)
👍️ 1
docsetc docsetc 3 months ago
Nice try?? Doofus. The HALB PR is still promoting them as an active element of their program. Take a look at the years and the pps. This is cooked hogwash. I wish your your sake it wasn't, but it is.
😄 1
retired early retired early 3 months ago
Defense Atomics Corp has been out for a long time. Old news but nice try. We ALL know Athena GTX is paving the way. :) .
👍️0
docsetc docsetc 3 months ago
Seems the naysayers had it right all along. Fools and their past money, parted a LONG time ago.
👍️ 1
docsetc docsetc 4 months ago
Especially in light of the fact that Defense Atomics Corp does not exist as a company anymore. Has not for quite a while.
👍️0
work-n-hard work-n-hard 4 months ago
" anecdotal evidence " That's why the PR fell flat. Sad, but true.
👍️ 1 🤣 1
retired early retired early 4 months ago
Good results from a problem that reaches worldwide. I'm already to see it hit a buck or get bought out. :)
👍️ 1 😜 1
EHRjunkie EHRjunkie 4 months ago
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System

Jackson Center, PA October 1, 2024 – Halberd Corporation (OTC-PINK: "HALB”) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veteran participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wore a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participant data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health.

During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.

Dr. Mark Darrah, CEO of Athena GTX, stated, “The results of this Pilot Study are very encouraging. We met all of our objectives set for this effort, helped the participants with improved health, and discovered ways we can improve the treatment methodology going forward. The proprietary LDX/CBN combination and specialized yoga/meditation positively impacted health and wellness, and the data acquisition system effectively supported participants. We will use what we learned plus feedback from participants to improve the treatment protocol as we proceed to a 100-patient Phase 1 clinical trial.”

Dr. Darrah continued, “As we enter the next programmed step, we wanted to remind any interested parties to consider enrolling in or supporting Phase 1 trials. This is an open invitation to witness first-hand the value and ease of the therapy and its impact.

William A. Hartman, President and CEO of Halberd Corporation, added, “The results thus far indicate the treatment methodology is having very promising results in the long-term care and treatment of patients suffering from PTSD and associated physical health issues. We remain hopeful that this will result in a widely accepted standard of care.”
👍️0
EHRjunkie EHRjunkie 4 months ago
mdiConsultants guiding the FDA clearance path
👍️0
EHRjunkie EHRjunkie 4 months ago
LDX will be on the market soon
👍️0
EHRjunkie EHRjunkie 4 months ago
Another 100 patient test will follow
👍️0
EHRjunkie EHRjunkie 4 months ago
New PR with test resulta
👍️0
work-n-hard work-n-hard 4 months ago
👍️0
XenaLives XenaLives 4 months ago
TOTAL NONSENSICAL B.S.



"While we have observed statistically compelling results in PTSD/TBI management using CRISPR," says CEO Dr. Gabe Vlad of Defense Atomics Corp., "the ability to significantly integrate our treatment protocols with those of Halberd/Athena's medication and monitoring technologies is quite attractive. The WatchDawg monitoring allows us to acquire near real time (NRT) objective data with respect to the administration of CRISPR. From the preliminary data, there's no question that theadds clear adjunctive relief."



The "LDX formulation" is an old failed drug see replied to post and the following:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880945/





There is
👍️ 1
work-n-hard work-n-hard 4 months ago
Good Day my friend. I believed we both learned back at BEBI, to take that profit and run.
As apposed to bagholding, or even worse, bagholding and try to keep other bagholders supporting your loosing position. 😜
👍️ 1
squidster squidster 4 months ago
They bought during the great HALB pump of 2021, I'm guessing around .05.-10 and have been holding the bag ever since...
👍️0
docsetc docsetc 4 months ago
Damn Squid, has any of these pathetically immature "investors" below realize 'Defense Atomics' is a fake company shell? We try to warn them fairly, and they just cuss and make threats, (BTW make them to my face scam-ees!) And they keep holding for dear life on this junk. Sue what's left of the fake Halberd clowns, maybe get more than what the current pps is right now.

Good lord.
👍️ 1
squidster squidster 4 months ago
Well, no one flips the POS better than you:)
👍️0
docsetc docsetc 4 months ago
This one I bash since it's' been a scam since company inception, and that last PR reads like a bad deep fake. For no other reason. Proven scams I don't forget.
Losers hang on when others warn them. I don't bash any stock much at all, not even ones that are just performance dogs, but if they are proven scams like HALB (?) No problem and I don't do it often either.

Bug off kid. Adults here now to protect your $$$, if you have any left at this point.
👍️ 1
docsetc docsetc 4 months ago
Sure. Have not owned a share of this for over 6 years now. After researching it closely, and discovering all of the scam operations, I go out at even money. The rest of you, I feel sorry for.

Your little blastoff rocket is grounded at this :"launch site".
👍️ 1
docsetc docsetc 4 months ago
LMAO!
👍️0
work-n-hard work-n-hard 4 months ago
You forgot bashing for cheap shares. (Just look at the volume. lol)
Who has to bash and then sit for who knows how long, on a bag of nothing? (Dead money is one of the dumbest things in Stinky Pinky Land.) SMH
Just wait for the PR and buy some. Hold for 5 mins. and release.
👍️0
squidster squidster 4 months ago
Just waiting for news...
Gobble up those cheapies they won't be here long...
Just waiting on those government contracts...
HALB to the moon...
Did I miss any?
👍️ 2
Aero-man Aero-man 4 months ago
That's right - when the PPS is manipulated down like this, load up. These game-playing schmendriks are doing longs a favor.
👍️0